NIBRT Annual Report 2019 announces strongest set of results

NIBRT today issued its Annual Report for 2019 which featured the strongest set of results across all areas of operation for the Institute.

The biopharma industry in Ireland continues to show strong growth with significant investments announced throughout 2019. NIBRT and its partners support these investments by providing world-class training and research on all aspects of biopharma manufacturing. Some of the key achievements in the year include:

  • Training 4,700 people on all aspects of biopharma manufacturing
  • Expansion of the Global Partner Programme with partners in Jefferson Institute of Bioprocessing, Philadelphia and University of Technology, Sydney, Australia
  • The launch of the NIBRT Online Academy
  • Progressing the Cell and Gene Forum Therapy (CGT), publishing a White Paper, commencing CGT training and commissioning concept design studies
  • Further development of the Biopharma 4.0 Alliance with Boston Consulting Group
  • Expansion of research activities and appointment of Prof Liz Topp as Chief Scientific Officer (CSO)
  • Winning Pharma Project of the Year with Siemens at Irish Pharma Awards and Staff Upskilling Award with Takeda at Invest in Ireland Awards

Commenting on NIBRT in 2019 Minister Heather Humphries TD, Minister for Business Enterprise and Innovation remarked, “We remain immensely proud to have the NIBRT world-class facility in our country. It’s justifiably recognised as a global leader in the provision of cutting-edge training and is cited, time and again, as a key factor in attracting new biopharmaceutical investment to Ireland.”

Announcing the Annual Report NIBRT CEO, Dominic Carolan stated “2019 was a year of significant growth across all aspects of our business. We saw our highest yet number of trainees through the facility with expanded training solutions being availed of by our clients. We were delighted to welcome our new CSO, Professor Elizabeth Topp, to the research team which had continued to expand its activities.”

NIBRT Chairman, Brendan O’Callaghan Senior Vice President and Global Head Biologics Platform, Sanofi noted “The success of the Irish biopharma industry is well noted and built on solid foundations. The global industry is now at an inflexion point and defining a broad Government life sciences strategy between all stakeholders, will greatly enhance Ireland’s competitiveness for new investments in manufacturing and research. However, there is a “need for speed” and stakeholders need to move immediately and at pace to keep pace with competing jurisdictions. NIBRT is ready and well-positioned to support and enable this next phase and we look forward with confidence to the opportunities ahead in 2020 and beyond.”

You can download the annual report  here